Future Procurement Opportunity (FPO) - Supply of adalimumab

Details

Tender Closed
RFx ID :	23934491
Tender Name :	Future Procurement Opportunity (FPO) - Supply of adalimumab
Reference # :	A1438691
Open Date :	Q1 2021
Indicative RFx Release Date  :	Q1 2021  [?]
Tender Type :	Future Procurement Opportunity (FPO)
Project Status :	Awaiting approval  [?]
Indicative Total Value :	$50M - $100M  [?]
Expected number of contracts offered :	1
Tender Coverage :	Sole Agency  [?]
Categories :	51000000 - Drugs and Pharmaceutical Products
Regions:	New Zealand
Required Pre-qualifications :	None
Contact :	PHARMAC Procurement Team procurement@Pharmac.govt.nz
Agency Address :

PHARMAC intends to issue a competitive process for the supply of adalimumab.

The approximate gross annual expenditure of adalimumab in the 2019/20 FYR was $95,000,000. Information related to the listing of adalimumab on the Pharmaceutical Schedule, including previous funding decisions is available on the PHARMAC website.

For current funding restrictions please view the Pharmaceutical Schedule which is available on the PHARMAC website.

As part of this potential procurement process PHARMAC may consider changes to funding restrictions.

This tender has been completed.

Date RFx was completed/updated: Thursday, 17 November 2022 9:38 AM (Pacific/Auckland UTC+13:00)